BioLineRx (BLRX) Research & Development (2013 - 2025)
BioLineRx (BLRX) recorded quarterly Research & Development of -$2.4 million in Q4 2025, down 41.07% quarter-over-quarter from -$1.7 million in Q3 2025, and down 30.03% on a YoY basis from -$3.5 million in Q4 2024.
BioLineRx (BLRX) Research & Development (2013 - 2025) Analysis & Trends
BioLineRx's Research & Development history runs 13 years deep, the most recent figure standing at -$2.4 million for Q4 2025.
- In Q4 2025, Research & Development fell 30.03% year-over-year to -$2.4 million; the TTM figure through Dec 2025 stood at -$8.1 million (up 11.54% YoY), while the FY2025 annual figure was -$8.1 million, up 11.54% from the prior year.
- Research & Development was -$2.4 million for Q4 2025 at BioLineRx, down from -$1.7 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $5.4 million in Q2 2022 to a low of -$5.1 million in Q4 2021.
- Historically, Research & Development has averaged -$2.3 million across 5 years, with a median of -$2.6 million in 2023.
- The sharpest annual moves came in 2023 and 2024: Research & Development tumbled 155.72% in 2023, then soared 39.88% in 2024.
- A 5-year view of Research & Development shows it stood at -$5.1 million in 2021, then soared by 33.09% to -$3.4 million in 2022, then advanced by 9.56% to -$3.1 million in 2023, then jumped by 39.88% to -$1.9 million in 2024, then tumbled by 30.03% to -$2.4 million in 2025.
- The last three Research & Development figures came in at -$2.4 million (Q4 2025), -$1.7 million (Q3 2025), and -$2.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -2.30 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 1.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -58.00 Mn |
| 10 | BioLineRx | 227.63 Mn | 211.90 Mn | 154,000.00 | -2.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.43 Mn |
| Sep 30, 2025 | -1.72 Mn |
| Jun 30, 2025 | -2.33 Mn |
| Mar 31, 2025 | -1.62 Mn |
| Dec 31, 2024 | -1.87 Mn |
| Sep 30, 2024 | -2.57 Mn |
| Jun 30, 2024 | -2.23 Mn |
| Mar 31, 2024 | -2.49 Mn |
| Dec 31, 2023 | -3.10 Mn |
| Sep 30, 2023 | -2.73 Mn |
| Jun 30, 2023 | -3.01 Mn |
| Mar 31, 2023 | -3.68 Mn |
| Dec 31, 2022 | -3.43 Mn |
| Sep 30, 2022 | -4.37 Mn |
| Jun 30, 2022 | 5.40 Mn |
| Mar 31, 2022 | -4.44 Mn |
| Dec 31, 2021 | -5.13 Mn |
| Sep 30, 2021 | -4.92 Mn |
| Jun 30, 2021 | 5.14 Mn |
| Mar 31, 2021 | -4.28 Mn |